Alamar Biosciences, Inc. (ALMR) Stock Analysis
Healthcare · Medical Devices · NasdaqGS
Alamar Biosciences, Inc. (ALMR) posted $74.21M in revenue for fiscal 2025 (up 195.2% year over year), with a net loss of $29.82M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Alamar Biosciences, Inc.
Alamar Biosciences, Inc. posted $74.21M in revenue in fiscal 2025. The most recent year was up 195.2%.
Net margin sits at -40.2%, up 147 points year over year on a 56.2% gross margin. It carries about $9.81M of total debt.
The one thing worth a second look in the filings is debt with negative operating cash flow.
Synthesised from Alamar Biosciences, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Alamar Biosciences, Inc. revenue & earnings — last 2 fiscal years
| Metric | 2024 | 2025 |
|---|---|---|
| Revenue | $25.14M | $74.21M |
| Gross profit | $8.61M | $41.70M |
| Net income | $-47.07M | $-29.82M |
| Net margin | -187.2% | -40.2% |
Source: Alamar Biosciences, Inc. SEC filings (10-K).
Alamar Biosciences, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Debt with negative operating cash flowCarries $9.8M of debt while last year's operating cash flow was negative ($-53.6M).
Explore 2 years of Alamar Biosciences, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ALMR in your portfolio →
Alamar Biosciences, Inc. financial history by metric
About Alamar Biosciences, Inc.
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. The company was incorporated in 2018 and is based in Fremont, California.
Alamar Biosciences, Inc. — frequently asked questions
What is Alamar Biosciences, Inc.'s revenue?
Alamar Biosciences, Inc. (ALMR) reported revenue of $74.21M for fiscal year 2025, up 195.2% from the prior year, according to its SEC filings.
Is Alamar Biosciences, Inc. profitable?
No — ALMR reported a net loss of $-29.82M in fiscal 2025.
What is ALMR's P/E ratio?
Alamar Biosciences, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Alamar Biosciences, Inc. have?
As of fiscal year 2025, ALMR carried roughly $9.81M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Alamar Biosciences, Inc.'s gross margin?
ALMR's gross margin was 56.2% in fiscal 2025 — gross profit of $41.70M on revenue of $74.21M.
What is Alamar Biosciences, Inc.'s market cap?
Alamar Biosciences, Inc. (ALMR) has a market capitalization of about $1.51B, based on the latest data in our nightly-refreshed cache.
When does Alamar Biosciences, Inc.'s fiscal year end?
ALMR's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Alamar Biosciences, Inc.'s official SEC filings (10-K and 10-Q), covering 2 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.